Journal article
Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
Abstract
AIMS: While genetic and biological studies indicated a potential association between proprotein-convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and hyperglycaemia, real-world data are limited. Therefore, we sought to investigate this association using the FDA adverse event reporting system (FAERS).
METHODS AND RESULTS: The FAERS database (2015-2020) was retrospectively queried to characterize reporting of hyperglycaemic adverse events …
Authors
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Journal
European Journal of Preventive Cardiology, Vol. 29, No. 9, pp. 1334–1342
Publisher
Oxford University Press (OUP)
Publication Date
July 20, 2022
DOI
10.1093/eurjpc/zwab209
ISSN
2047-4873